
|Articles|October 18, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemia
Author(s)Mark Weiss, MD
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.
Advertisement
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia, including BTK and PI3K inhibitors.
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?
Articles in this issue
about 12 years ago
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myelomaabout 12 years ago
Clinical Advances in Mantle Cell Lymphomaabout 12 years ago
Emerging Therapies for the Treatment of Mantle Cell Lymphomaabout 12 years ago
In Brief: Phase III Trials in Multiple Myelomaabout 12 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?about 12 years ago
Transforming Expectations and Outcomes With Targeted Therapiesabout 12 years ago
The Utility of Pomalidomide in R/R Multiple Myelomaabout 12 years ago
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHLAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
Exploring the IO Interface: Bridging Knowledge Gaps in Immunotoxicity Management
3
Medication Burden Linked With Acute Care Use in ARSI-Treated Prostate Cancer
4
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
5






































